AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2955-2966

  Zabludoff, Sonya D ^a   Deng, Chun ^a   Grondine, Michael R ^a   Sheehy, Adam M ^a   Ashwell, Susan ^a   Caleb, Benjamin L ^a   Green, Stephen ^a   Haye, Heather R ^a   Horn, Candice L ^a   Janetka, James W ^a   Liu, Dongfang ^a   Mouchet, Elizabeth ^a   Ready, Shannon ^a   Rosenthal, Judith L ^a   Queva, Christophe ^a   Schwartz, Gary K ^b   Taylor, Karen J ^a   Tse, Archie N ^b   Walker, Graeme E ^a   White, Anne M ^a  

^a ASTRAZENECA   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (CARBAMOYLAMINO) 5 (3 FLUOROPHENYL) N [3 PIPERIDYL]THIOPHENE 2 CARBOXAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; AZD 7762; GEMCITABINE; IRINOTECAN; PHOSPHOTRANSFERASE INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; DNA DAMAGE; DOSE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; BIOLOGICAL ASSAY; CELL CYCLE PROTEINS; CELL DEATH; DEOXYCYTIDINE; DNA DAMAGE; DNA, NEOPLASM; DRUG SYNERGISM; G2 PHASE; HCT116 CELLS; HT29 CELLS; HUMANS; MALE; MICE; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RATS; THIOPHENES; TOPOTECAN; TUMOR SUPPRESSOR PROTEIN P53; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 52949139387     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0492     Document Type: Article

References (37)

1. Lau CC, Pardee AB. Mechanismby which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci U S A 1982;79:2942-6.
2. Musk SRR, Steel GG. Override of the radiation-induced mitotic block in human tumor cells by methylxanthines and its relationship to the potentiation of cytotoxicity. Int J Radiat Biol 1990;57:1105-12.
3. Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B, Jr. Efficacy of pentoxyfylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res 1991;11:1555-60.
4. 1 checkpoint-competent cells. Cancer Res 1995;55:1639-42.
5. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells disrupted with p53. J Natl Cancer Inst 1996;88:956-65.
6. Graves PR, Yu L, Schwarz JK, Gales J, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem2000;275:56 00-5.
7. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60:2108-12.
8. 2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001;20:7453-63.
9. 2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. Anticancer Res 2001;21:23-8.
10. 2 checkpoint mechanism. Neoplasia 2001;3:411-9.
11. 2 checkpoints. Proc Natl Acad Sci U S A 2002;99:14795-800.
12. 2 DNA damage checkpoint. Mol Cancer Ther 2003;2:543-8.
13. Takahashi I, Saitoh Y, Yoshida M, et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J Antibiot 1989;42:571-6.
14. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 1996;219:778-83.
15. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-dependent cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007;11:175-89.
16. Karnitz LM, Flatten KS, Wagner JM, et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 2005;68:1636-44.
17. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 2005;65:6835-42.
18. Sanchez Y, Wong C, Thoma RS, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997;277:1497-501.
19. Mailand N, Falck J, Lukas C, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000;288:1425-9.
20. Sampath D, Shi Z, Plunkett W. Inhibition of cyclin-dependent kinase 2 by the Chk1-25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystraurosporine. Mol Pharmacol 2002;62:680-8.
21. Sorensen CS, Syljuasen RG, Falck J, et al. Chk1 regulated the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003;3:247-58.
22. 2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem2003;278:21 767-73.
23. Flatten K, Dai NT, Vroman BT, et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 2005;280:14349-55.
24. 2 checkpoint control: regulation of 14-3-3-protein binding by phosphorylation of cdc25Con serine-216. Science 1997;277:1501-5.
25. Chan TA, Hermeking H, Lengauer, Kinzler KW, Vogelstein B. 14-3-3j is required to prevent catastrophe after DNA damage. Nature 1999;401:616-20.
26. Sampath D. Rao VA. Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003;22:9063-74.
27. Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, Caldecott KW. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 2006;26:3319-26.
28. Xiao Z, Xue J, Sowin TJ, Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2 and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage induced cell cycle arrest: implication for cancer therapy. Mol Cancer Ther 2006;5:1935-43.
29. 2M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350. Biochem Biophys Res Commun 2002;295:435-44.
30. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005;4:131-9.
31. Carrassa L, Broggini M, Erba E, Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents. Cell Cycle 2004;3:1177-81.
32. Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 2007;6:935-44.
33. Matthews D. In vitro and in vivo potentiation of cytotoxic therapy by XL844, an orally bioavailable inhibitor of Chk1 and Chk2 [abstract B228]. Proc AACR-NCI-EORTC 2007.
34. Blasina A, Kornmann JF, Chen E, Anderes K. A novel inhibitor of the protein kinase CHK1: studies on the mechanism of action. Proc Am Assoc Cancer Res 2005;46:Abs 4416.
35. Hollingshead MG, Alley MC, Camalier RF, et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci 1995;57:131-41.
36. Hall LA, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM, Kerr JS. The hollow fiber assay: continued characterization with novel approaches. Anticancer Res 2000;20:903-11.
37. Suggitt M, Swaine DJ, Pettit GR, Bibby MC. Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo. Clin Cancer Res 2004;10:6677-85.